Nanomedicines in the treatment of acromegaly: focus on pegvisomant

References

• AbsRVerhelstJMaiterD1998Cabergoline in the treatment of acromegaly:a study in 64 patientsJ Clin Endocrinol Metab8337489467544
   PubMed Web of Science ®Google Scholar
• AhmedSElsheikhMStrattonIM1999Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experienceClin Endocrinol (Oxf)50561710468920
   PubMed Web of Science ®Google Scholar
• AlexanderLAppletonDHallR1980Epidemiology of acromegaly in the Newcastle regionClin Endocrinol (Oxf)127197379316
   PubMed Web of Science ®Google Scholar
• Alves dos SantosCMten BroekeTStrousGJ2001Growth hormone receptor ubiquitination, endocytosis, and degradation are independent of signal transduction via Janus kinase 2J Biol Chem276326354111418602
   PubMed Web of Science ®Google Scholar
• AttanasioREpaminondaPMottiE2003Gamma-knife radiosurgery in acromegaly: A 4-Year follow-up studyJ Clin Endocrinol Metab8831051212843150
   PubMed Web of Science ®Google Scholar
• BaumannG1991Growth hormone heterogeneity: genes, isohormones, variants, and binding proteinsEndocr Rev12424491760996
   PubMed Web of Science ®Google Scholar
• BarkanALBurmanPClemmonsDR2005Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomantJ Clin Endocrinol Metab9056849116076947
   PubMed Web of Science ®Google Scholar
• BazanJF1990Structural design and molecular evolution of a cytokine receptor superfamilyProc Natl Acad Sci U S A87639348
   Web of Science ®Google Scholar
• BehnckenSNWatersMJ1999Molecular recognition events involved in the activation of the growth hormone receptor by growth hormoneJ Mol Recognit123556210611645
   PubMed Web of Science ®Google Scholar
• Ben ShlomoAMelmedS2003The role of pharmacotherapy in peri-operative management of patients with acromegalyJ Clin Endocrinol Metab88963812629068
   PubMed Web of Science ®Google Scholar
• BengtssonBAEdenSErnestI1988Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984Acta Med Scand223327353369313
   PubMed Web of Science ®Google Scholar
• BengtssonBABrummerRJEdenS1989Body composition in acromegalyClin Endocrinol (Oxf)30121302612014
   PubMed Web of Science ®Google Scholar
• BieringHSallerBBauditzJ2006Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitisEur J Endocrinol1542132016452533
   PubMed Web of Science ®Google Scholar
• BiermaszNRDekkerFWPereiraAM2004Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor-I measurementsJ Clin Endocrinol Metab8927899615181059
   PubMed Web of Science ®Google Scholar
• BiermaszNRvan DulkenHRoelfsemaF1999Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotideJ Clin Endocrinol Metab843551510522994
   PubMed Web of Science ®Google Scholar
• BiermaszNRvan DulkenHRoelfsemaF2000aPostoperative radio-therapy in acromegaly is effective in reducing GH concentration to safe levelsClin Endocrinol (Oxf)533212710971449
   PubMed Web of Science ®Google Scholar
• BiermaszNRvan DulkenHRoelfsemaF2000bLong-term follow-up results of postoperative radiotherapy in 36 patients with acromegalyJ Clin Endocrinol Metab8524768210902796
   PubMed Web of Science ®Google Scholar
• BiermaszNRvan DulkenHRoelfsemaF2000cTen-year follow-up results of transsphenoidal microsurgery in acromegalyJ Clin Endocrinol Metab85459660211134114
   PubMed Web of Science ®Google Scholar
• BiermaszNRPereiraAMNeelisKJ2006The role of radiotherapy in the management of acromegalyExpert Rev Endocrinol MetabIn press.
   Google Scholar
• BiermaszNRPereiraAMSmitJW2005Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegalyGrowth Horm IGF Res15200615935982
   PubMed Web of Science ®Google Scholar
• BrownRJAdamsJJPelekanosRA2005Model for growth hormone receptor activation based on subunit rotation within a receptor dimerNat Struct Mol Biol128142116116438
   PubMed Web of Science ®Google Scholar
• Carter-SuCSmitLS1998Signaling via JAK tyrosine kinases: growth hormone receptor as a model systemRecent Prog Horm Res5361829769703
   PubMedGoogle Scholar
• ChenWYWightDCWagnerTE1990aExpression of a mutated bovine growth hormone gene suppresses growth in transgenic miceProc Natl Acad Sci U S A875061652367524
   PubMed Web of Science ®Google Scholar
• ChenWYWightDCChenNY1991Mutations in the third α-helix of bovine growth hormone dramatically affect its intracellular distribution in vitro and growth enhancement in transgenic miceJ Biol Chem266225281989980
   PubMed Web of Science ®Google Scholar
• ChenWYChenNYYunJ1994In vitro and in vivo studies of antagonistic effects of human growth hormone analogsJ Biol Chem2691589278195244
   PubMed Web of Science ®Google Scholar
• ClarkROlsonKFuhG1996Long-acting growth hormones produced by conjugation with polyethylene glycolJ Biol Chem27121969778703002
   PubMed Web of Science ®Google Scholar
• ColaoAFeroneDMarzulloP2004Systemic complications of acromegaly: epidemiology, pathogenesis, and managementEndocr Rev251025214769829
   PubMed Web of Science ®Google Scholar
• CozziRAttanasioRMontiniM2003Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?J Clin Endocrinol Metab883090812843148
   PubMed Web of Science ®Google Scholar
• CozziRAttanasioRLodriniS2004Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin statusClin Endocrinol (Oxf)612091515272916
   PubMed Web of Science ®Google Scholar
• CozziRMontiniMAttanasioR2006Primary treatment of acromegaly with octreotide LAR: A long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkageJ Clin Endocrinol Metab91139740316449332
   PubMed Web of Science ®Google Scholar
• DavisFFAbuchowskiAvan EsT1978Enzyme-polyethylene glycol adducts: modified enzymes with unique propertiesEnzyme Eng416973
   Google Scholar
• de VosAMUltschMKossiakoffAA1992Human growth hormone and extracellular domain of its receptor: crystal structure of the complexScience255306121549776
   PubMed Web of Science ®Google Scholar
• DrakeWMRowlesSVRobertsME2003Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomantEur J Endocrinol149521714640992
   PubMed Web of Science ®Google Scholar
• EzzatSForsterMJBerchtoldP1994Acromegaly. Clinical and biochemical features in 500 patientsMedicine (Baltimore)73233407934807
   PubMed Web of Science ®Google Scholar
• FairfieldWPSesmiloGKatznelsonL2002Effects of a growth hormone receptor antagonist on bone markers in acromegalyClin Endocrinol5738590
   PubMed Web of Science ®Google Scholar
• FeenstraJde HerderWWten HaveSMTH2005Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegalyThe Lancet36516446
   PubMed Web of Science ®Google Scholar
• FredaPUWardlawSLPostKD1998Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegalyJ Neurosurg8935389724106
   PubMed Web of Science ®Google Scholar
• FredaPU2003Current concepts in the biochemical assessment of the patient with acromegalyGrowth Horm IGF Res131718412914750
   PubMed Web of Science ®Google Scholar
• FuhGCunninghamBCFukunagaR1992Rational design of potent antagonists to the human growth hormone receptorScience2561677801535167
   PubMed Web of Science ®Google Scholar
• GentJVan den EijndenMvan KerkhofP2003Dimerization and signal transduction of the growth hormone receptorMol Endocrinol179677512576487
   PubMedGoogle Scholar
• GilbertJAMiellJPChambersSM2005The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegalyClin Endocrinol (Oxford)622828
   Web of Science ®Google Scholar
• GiustinaAVeldhuisJD1998Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the humanEndocr Rev19717979861545
   PubMed Web of Science ®Google Scholar
• GiustinaABarkanACasanuevaFF2000Criteria for cure of acromegaly: a consensus statementJ Clin Endocrinol Metab85526910690849
   PubMed Web of Science ®Google Scholar
• GoffinVBernichteinSCarriereO1999The growth hormone antagonist B2036 does not interact with the prolactin receptorEndocrinology1403853610433247
   PubMed Web of Science ®Google Scholar
• HardingPAWangXOkadaS1996Growth hormone (GH) and a GH antagonist promote GH receptor dimerization and internalizationJ Biol Chem2716708128636090
   PubMed Web of Science ®Google Scholar
• HarrisJMMartinNEModiM2001Pegylation: a novel process for modifying pharmacokineticsClin Pharmacokinet405395111510630
   PubMed Web of Science ®Google Scholar
• HoKYWeisbergerAJ1994Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapyClin Endocrinol (Oxford)417583
   PubMed Web of Science ®Google Scholar
• HoflandLJLambertsSWJ2003The pathophysiological consequences of somatostatin receptor internalization and resistanceEndocr Rev24284712588807
   PubMed Web of Science ®Google Scholar
• HoffmanDMO’SullivanAJBaxterRC1994Diagnosis of growth hormone deficiency in adultsLancet343106487512681
   PubMed Web of Science ®Google Scholar
• JaffeCABarkanAL1992Treatment of acromegaly with dopamine agonistsEndocrinol Metab Clin North Am21713351355728
   PubMed Web of Science ®Google Scholar
• JanssenYJHFrolichMRoelfsemaF1997A low starting dose of recombinant human growth hormone (GH) in adults with GH deficiencyJ Clin Endocrinol Metab82129358989246
   PubMed Web of Science ®Google Scholar
• JehleSReyesCMSundeenRE2005Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegalyJ Clin Endocrinol Metab9015889315585549
   PubMed Web of Science ®Google Scholar
• JørgensenJOLFeldt-RasmusenUFrystykJ2005Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonistJ Clin Endocrinol Metab9056273116046586
   PubMed Web of Science ®Google Scholar
• KaravitakiNBotusanIRadianS2005The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegalyClin Endocrinol (Oxf)62282815730408
   PubMed Web of Science ®Google Scholar
• KaulsayKKZhuTBennettWF2001The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptorEndocrinology1427677711159849
   PubMed Web of Science ®Google Scholar
• KojimaMHosodaHDateY1999Ghrelin is a growth-hormone-releasing acylated peptide from stomachNature4026566010604470
   PubMed Web of Science ®Google Scholar
• LancranjanIAtkinsonABSandostatin LAR Group1999Results of a European multicentre study with Sandostatin LAR in acromegalic patientsPituitary11051411081188
   PubMedGoogle Scholar
• LandoltAMHallerDLomaxN1998Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapyJ Neurosurg88100289609294
   PubMed Web of Science ®Google Scholar
• LaronZPertzelanAMannheimerS1966Genetic pituitary dwarfism with high serum concentrations of growth hormone – a new inborn error of metabolism?Isr J Med Sci215255916640
   PubMedGoogle Scholar
• Le RoithDBondyCYakarS2001The somatomedin hypothesisEndocr Rev22537411159816
   PubMed Web of Science ®Google Scholar
• LongHBeauregardHSommaM1996Surgical outcome after repeated transsphenoidal surgery in acromegalyJ Neurosurg85239478755752
   PubMed Web of Science ®Google Scholar
• LowmanHBWellsJA1993Affinity maturation of human growth hormone by monovalent phage displayJ Mol Biol234564788254660
   PubMed Web of Science ®Google Scholar
• MaamraMFinidoriJvon LaueS1999Studies with a growth hormone antagonist and dual-fluorescent confocal microscopy demonstrate that the full-length human growth hormone receptor, but not the truncated isoform, is very rapidly internalized independent of Jak2-Stat5 signalingJ Biol Chem27414791810329677
   PubMed Web of Science ®Google Scholar
• McCutcheonIEFlyvbjergAHillH2001Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude miceJ Neurosurg944879211235955
   PubMed Web of Science ®Google Scholar
• Mahmoud-AhmedASSuhJHMaybergMR2001Gamma knife radio-surgery in the management of patients with acromegaly: a reviewPituitary42233012501972
   PubMedGoogle Scholar
• MeinhardtUEbleABessonA2003Regulation of growth-hormone-receptor gene expression by growth hormone and pegvisomant in human mesangial cellsKidney Int644213012846737
   PubMed Web of Science ®Google Scholar
• MelmedSSternbergRCookD2005A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegalyJ Clin Endocrinol MetabDOI 10.1210/jc.2004–2466.
   Web of Science ®Google Scholar
• MestronAWebbSMAstorgaR2004Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA)Eur J Endocrinol1514394615476442
   PubMed Web of Science ®Google Scholar
• MurrayRDKimKRenS-G2004Central and peripheral actions of somatostatin on the growth hormone-IGF-I axisJ Clin Invest1143495615286801
   PubMed Web of Science ®Google Scholar
• NassRToogoodAAHellmannP2000Intracerebroventricular administration of the rat growth hormone (GH) receptor antagonist G118R stimulates GH secretion: evidence for the existence of short loop negative feedback of GHJ Neuroendocrinol121194911106977
   PubMed Web of Science ®Google Scholar
• ParkinsonCDrakeWMRobertsME2002aA comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed mealJ Clin Endocrinol Metab87179780411932320
   PubMed Web of Science ®Google Scholar
• ParkinsonCDrakeWMWieringaW2002bSerum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegalyClin Endocrinol5630311
   PubMed Web of Science ®Google Scholar
• ParkinsonCWhatmoreAJYatesAP2003aThe effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegalyClin Endocrinol5916874
   PubMed Web of Science ®Google Scholar
• ParkinsonCKassemMHeickendorffL2003bPegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normalJ Clin Endocrinol Metab885650514671148
   PubMed Web of Science ®Google Scholar
• PelekanosRAWatersMJ2006Activation of the growth hormone receptorExpert Rev Endocrinol Metab118998
   PubMedGoogle Scholar
• PijlHLangendonkJGBurggraafJ2001Altered neuroregulation of GH secretion in viscerally obese premenopausal womenJ Clin Endocrinol Metab865509551511701729
   PubMed Web of Science ®Google Scholar
• PradhanangaSWilkinsonIRossRJM2002Pegvisomant: structure and functionJ Mol Endocrinol2911412200225
   PubMed Web of Science ®Google Scholar
• RitchieCMAtkinsonABKennedyAL1990Ascertainment and natural history of treated acromegaly in Northern IrelandUlster Med J5955622349750
   PubMedGoogle Scholar
• RodvoldKABennettWFZibKA1997Single-dose safety and pharmacokinetics of B2036-PEG (Somavert) after subcutaneous administration in healthy volunteers [abstract]J Clin Pharmacol37869
   Web of Science ®Google Scholar
• RodvoldKAvan der LelyAJ1999Pharmacokinetics and pharmacodynamics of B2036-PEG, a novel growth hormone receptor antagonist, in acromegalic subjects [abstract]Proceedings 81th annual meeting of the Endocrine Society1049
   Google Scholar
• RoelfsemaFGoslingsBMFrolichM1979The influence of bromocriptin on serum levels of growth hormone and other pituitary hormones and its metabolic effects in active acromegalyClin Endocrinol (Oxf)1123544114344
   PubMed Web of Science ®Google Scholar
• RoelfsemaFBiermaszNRRomijnJA2005Treatment strategies for acromegalyExpert Opin Emerging Drugs1087590
   PubMedGoogle Scholar
• RoseDRClemmonsDR2002Growth hormone receptor antagonist improves insulin resistance in acromegalyGrowth Horm IGF Res124182412423627
   PubMed Web of Science ®Google Scholar
• RosenbloomAL2000Physiology and disorders of the growth hormone receptor (GHR) and GH-GHR signal transductionEndocrine121071910905371
   PubMed Web of Science ®Google Scholar
• RossRJLeungKCMaamraM2001Binding and functional studies with the growth hormone receptor antagonist B2056-PEG (pegvisomant) reveal effects of pegylation and evidence that it binds to a receptor dimmerJ Clin Endocrinol Metab8617162311297608
   PubMed Web of Science ®Google Scholar
• SerriOBrazeauPKachraZ1992Octreotide inhibits insulin-like growth factor-I hepatic gene expression in hypophysectomized rat: evidence for a direct and indirect mechanism of actionEndocrinology1301816211547711
   PubMed Web of Science ®Google Scholar
• SesmiloGFairfieldWPKatznelsonL2002Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomantJ Clin Endocrinol Metab871692911932303
   PubMed Web of Science ®Google Scholar
• SjogrenKLiuJLBladK1999Liver-derived insulin-like growth factor I (IGF-I) is the principle source of IGF-I in blood but it is not required for postnatal body growth in miceProc Natl Acad Sci U S A9670889210359843
   PubMed Web of Science ®Google Scholar
• SjogrenKJanssonJOIsakssonOG2002A model for tissue-specific inducible insulin-like growth factor (IGF-I) inactivation to determine the physiological role of liver-derived IGF-IEndocrine192495612624424
   PubMed Web of Science ®Google Scholar
• SotiropoulosAGoujonLSimoninG1993Ece for generation of the growth hormone-binding protein through proteolysis of the growth hormone membrane receptorEndocrinology132186358462483
   PubMed Web of Science ®Google Scholar
• StrousGJAlves dos SantosCGentJ2004Ubiquitin system –dependent regulation of growth hormone receptor signal transductionCurr Top Microbiol Immunol2868111815645711
   PubMed Web of Science ®Google Scholar
• SwaeringenBBarkerFGKatznelsonL1998Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegalyJ Clin Endocrinol Metab83341189768640
   PubMed Web of Science ®Google Scholar
• TachasGLofthouseSWraight2006A GH receptor antisense oligonucleotide inhibits hepatic GH receptor expression, IGF-I production and body weight gain in normal miceJ Endocrinol1891475416614389
   PubMed Web of Science ®Google Scholar
• ThornerMOStrasburgerCJWuZ1999Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GHJ Clin Endocrinol Metab84209810310372717
   PubMed Web of Science ®Google Scholar
• TrainerPJDrakeWMKatznelsonL2000Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomantN Engl J Med3421171710770982
   PubMed Web of Science ®Google Scholar
• TrainerPJDrakeWMPerryLA2001Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegalyJ Clin Endocrinol Metab8629899211443156
   PubMed Web of Science ®Google Scholar
• UltschMde VosAMKossiakoffAA1991Crystals of the complex between human growth hormone and the extracellular domain of its receptorJ Mol Biol22286581762154
   PubMed Web of Science ®Google Scholar
• UltschMde VosAM1993Crystals of growth hormone –receptor complexes. Extracellular domains of the growth hormone and prolactin receptors and a hormone mutant designed to prevent receptor dimerizationJ Mol Biol2311133368515471
   PubMed Web of Science ®Google Scholar
• UltschMHSomersWKossiakoffAA1994The crystal structure of affinity-matured growth hormone at 2 Å resolutionJ Mol Biol236286998107110
   PubMed Web of Science ®Google Scholar
• Van den BergGFrolichMVeldhuisJD1994Growth hormone secretion in recently operated acromegalic patientsJ Clin Endocrinol Metab791706157989479
   PubMed Web of Science ®Google Scholar
• van den BergGPincusSMFrolichM1998Reduced disorderliness of growth hormone release in biochemically inactive acromegaly after pituitary surgeryEur J Endocrinol13816499506860
   PubMed Web of Science ®Google Scholar
• van der LelyAJde HerderWWJanssenJA1997Acromegaly:the significance of serum total and free IGF-I and IGF- binding protein-3 in diagnosisJ Endocrinol155Suppl 1S913discussion S15–6: S9–13.9389990
   PubMed Web of Science ®Google Scholar
• van der LelyAJHutsonRKTrainerPJ2001Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonistLancet3581754911734231
   PubMed Web of Science ®Google Scholar
• van KerkhofPSmeetsMStrousGJ2002The ubiquitin-proteasome pathway regulates the availability of the GH receptorEndocrinol143124352
   PubMed Web of Science ®Google Scholar
• van NeckJWDitsNFJCingelV2000Dose-response effects of a new growth hormone receptor antagonist (B2036-PEG) on circulating, hepatic and renal expression of the growth hormone/insulin-like growth factor system in adult miceJ Endocrinol16729530311054644
   PubMed Web of Science ®Google Scholar
• van NeckJWCingelVvan VlietAK2002High-protein induced renal enlargement is growth hormone independentKidney Int6211879512234289
   PubMed Web of Science ®Google Scholar
• VeldhuisJDBidlingmaierMAndersonSM2001Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-Peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and menJ Clin Endocrinol Metab8633041011443205
   PubMed Web of Science ®Google Scholar
• WalenkampMJEKarperienMPereiraAM2005Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutationJ Clin Endocrinol Metab9028556415769976
   PubMed Web of Science ®Google Scholar
• WassJA2003Radiotherapy in acromegaly: a protagonist’s viewpointClin Endocrinol (Oxf)581283112580924
   PubMed Web of Science ®Google Scholar
• WilsonME2000Insulin-like growth factor-I (IGF-I) replacement during growth hormone receptor antagonism normalizes serum IGF-binding protein-3 and markers of bone formation in ovariectomized rhesus monkeysJ Clin Endocrinol Metab8515576210770197
   PubMed Web of Science ®Google Scholar
• WoodsKACamacho-HubnerCSavageMO1996Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I geneN Eng J Med33513637
   PubMed Web of Science ®Google Scholar
• WrightADHillDMLowyC1970Mortality in acromegalyQ J Med391165427331
   PubMedGoogle Scholar